Equities research analysts forecast that AxoGen, Inc (NASDAQ:AXGN) will report $22.20 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for AxoGen’s earnings. The highest sales estimate is $22.50 million and the lowest is $21.90 million. AxoGen posted sales of $17.26 million during the same quarter last year, which suggests a positive year-over-year growth rate of 28.6%. The firm is scheduled to announce its next earnings report on Monday, April 29th.

On average, analysts expect that AxoGen will report full year sales of $114.27 million for the current fiscal year, with estimates ranging from $109.90 million to $121.10 million. For the next financial year, analysts forecast that the company will report sales of $149.10 million, with estimates ranging from $147.30 million to $150.90 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow AxoGen.

AxoGen (NASDAQ:AXGN) last released its earnings results on Tuesday, February 26th. The medical equipment provider reported ($0.09) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. AxoGen had a negative net margin of 26.68% and a negative return on equity of 15.77%. The business had revenue of $23.40 million during the quarter, compared to analysts’ expectations of $23.40 million. During the same quarter last year, the company earned ($0.07) earnings per share. The firm’s revenue was up 37.6% on a year-over-year basis.

A number of brokerages have commented on AXGN. BidaskClub upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Wednesday, March 6th. Cantor Fitzgerald restated a “buy” rating and set a $43.00 price target on shares of AxoGen in a research note on Wednesday, December 19th. ValuEngine cut shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. Finally, BTIG Research raised shares of AxoGen from a “neutral” rating to a “buy” rating and set a $28.00 price objective for the company in a report on Monday, March 25th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $38.00.

AXGN traded down $0.23 during midday trading on Friday, reaching $21.60. 16,307 shares of the company’s stock were exchanged, compared to its average volume of 445,382. The stock has a market cap of $830.01 million, a price-to-earnings ratio of -39.80 and a beta of 0.17. AxoGen has a one year low of $14.13 and a one year high of $56.85.

Several hedge funds and other institutional investors have recently bought and sold shares of AXGN. Deutsche Bank AG increased its holdings in shares of AxoGen by 190.3% in the fourth quarter. Deutsche Bank AG now owns 225,476 shares of the medical equipment provider’s stock valued at $4,605,000 after purchasing an additional 147,798 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of AxoGen by 7.9% in the fourth quarter. Geode Capital Management LLC now owns 383,278 shares of the medical equipment provider’s stock valued at $7,830,000 after purchasing an additional 28,111 shares in the last quarter. Norges Bank acquired a new stake in shares of AxoGen in the fourth quarter valued at approximately $1,029,000. Penn Capital Management Co. Inc. acquired a new stake in shares of AxoGen in the fourth quarter valued at approximately $1,381,000. Finally, Macquarie Group Ltd. increased its holdings in shares of AxoGen by 39.6% in the fourth quarter. Macquarie Group Ltd. now owns 38,811 shares of the medical equipment provider’s stock valued at $793,000 after purchasing an additional 11,017 shares in the last quarter. 89.19% of the stock is owned by institutional investors.

AxoGen Company Profile

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Featured Story: Why do companies pay special dividends?

Get a free copy of the Zacks research report on AxoGen (AXGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.